Active, not recruitingPhase 3NCT06564142
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alpine Immune Sciences Inc, A Subsidiary of Vertex
- Intervention
- Povetacicept(drug)
- Enrollment
- 605 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- Apogee Clinical Research, LLC, Huntsville, Alabama, United States
- Arizona Kidney Disease and Hypertension Center - Thomas Office, Phoenix, Arizona, United States
- Arizona Kidney Disease and Hypertension Center - Tuscon, Tucson, Arizona, United States
- West Coast Kidney, Fremont, California, United States
- The Medical Research Group, Inc. (FRENOVA), Fresno, California, United States
- CARE Institute - Carabello Kidney, Los Angeles, California, United States
- Providence Medical Foundation - Orange, Orange, California, United States
- National Nephrology Alliance Research, Riverside, California, United States
- UC Davis Health, Sacramento, California, United States
- Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California, United States
- University of California San Francisco (UCSF), San Francisco, California, United States
- Western Nephrology, Arvada, Colorado, United States
- Colorado Kidney Care, Denver, Colorado, United States
- Nephrology Associates Delaware Kidney (FRENOVA), Newark, Delaware, United States
- South Florida Nephrology Group PA, Research Div., Coral Springs, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06564142 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital